Key result
Antiplatelet therapy reaches only ~47% of visits for patients with ischemic vascular disease.
Why the study?
Antiplatelet medications were prescribed in less than half of visits for patients with ischemic vascular disease despite evidence supporting aspirin's cardiovascular benefits.
There is a substantial opportunity to improve secondary prevention of cardiovascular disease by increasing the prescription of aspirin and other antiplatelet medications.
Underuse of antiplatelet therapy in secondary prevention persists; leaves open the need for implementation research to close the gap.
In 2007–2008, antiplatelet medications were prescribed at only 46.9% of visits for patients with ischemic vascular disease. The evidence of the benefit of aspirin with respect to cardiovascular outcomes underscores the substantial opportunity before clinicians and patients.
No takes yet. Share an insight, caveat, or question.
Parekh et al. (2013) studied this question. Antiplatelet medications were prescribed at only 46.9% of visits for patients with ischemic vascular disease in 2007–2008, despite the known cardiovascular benefits of aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: